Abstract
Tears of the retinal pigment epithelium (RPE) are a known and potentially catastrophic complication of exudative age-related macular degeneration (AMD). Eyes with vascularized retinal pigment epithelial detachments (PED) are especially at risk for the development of RPE tears. This long-recognized complication faces increased scrutiny in an era of improved anti-angiogenic treatments for AMD, particularly given that these newly developed therapeutics have been implicated as a potential factor in the formation of some RPE tears.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Angiogenesis Inhibitors / therapeutic use
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Humanized
-
Bevacizumab
-
Exudates and Transudates
-
Humans
-
Macular Degeneration / complications*
-
Macular Degeneration / drug therapy*
-
Macular Degeneration / physiopathology
-
Retinal Perforations / etiology*
-
Retinal Perforations / physiopathology
-
Retinal Pigment Epithelium / pathology
-
Rupture, Spontaneous
-
Vascular Endothelial Growth Factor A / antagonists & inhibitors
Substances
-
Angiogenesis Inhibitors
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
VEGFA protein, human
-
Vascular Endothelial Growth Factor A
-
Bevacizumab